Skip to main content
Tracy I. George, MD
Chief Scientific Officer
Medical Director: Hematopathology
Specialties
Hematopathology
Laboratory hematology
Education
Medical Degree—University of California, San Francisco School of Medicine
Residency—Pathology and Laboratory Medicine, University of California, San Francisco School of Medicine
Fellowship—Hematopathology, Stanford University School of Medicine
Fellowship—Surgical Pathology, Stanford University School of Medicine
Current/Past Roles
Chief Medical Officer, ARUP Laboratories
Executive Director, Clinical Trials and PharmaDx, ARUP Laboratories
Vice Chair of Clinical Affairs, University of New Mexico Department of Pathology
Past President of the International Society for Laboratory Hematology
Secretary/Treasurer of the American Initiative in Mast Cell Diseases (AIM)
Certification/Affiliations
American Board of Pathology (Anatomic and Clinical Pathology, Hematology)
Research Interests
Mast cell disease
Translational hematopathology
Laboratory hematology
Awards
Healthcare Hero, Utah Business Magazine
Lifetime Achievement Award, College of American Pathologists
First Annual Dr. Steve Chen Hematopathology Lectureship, University of New Mexico
Recent Publications
Al-Ghamdi YA, et al. Triple-negative primary myelofibrosis: A Bone Marrow Pathology Group study . Mod Pathol . 2023;36(3):100016.
Cantu MD, et al. Clinicopathologic and molecular analysis of normal karyotype therapy-related and de novo acute myeloid leukemia: A multi-institutional study by the Bone Marrow Pathology Group . JCO Precis Oncol . 2023;7:e2200400.
Frater JL, et al. Arterial blood as an alternative specimen source for complete blood cell count: More human studies are needed . Int J Lab Hematol . 2023;45(3):e90–92.
Konantz M, et al. Increased TIM-3 and GAL-9 serum levels in patients with advanced systemic mastocytosis . J Allergy Clin Immunol . 2023;S0091-6749(23):00860–6.
Kumar J, et al. Smoking status in acute myeloid leukemia is associated with worse overall survival and independent of prior nonhematopoietic malignancies, cytogenetic abnormalities, and WHO category . Hum Pathol . 2023;135:45–53.
Leguit RJ, et al. The international consensus classification of mastocytosis and related entities . Virchows Arch . 2023;482(1):99–112.
Ohgami RS, et al. An analysis of the pathologic features of blastic plasmacytoid dendritic cell neoplasm based on a comprehensive literature database of cases . Arch Pathol Lab Med . 2023;147(7):837–46.
Patel JL, et al. Genomic data heterogeneity across molecular diagnostic laboratories: A real-world Connect Myeloid Disease Registry perspective on variabilities in genomic assay methodology and reporting . J Mol Diagn . 2023;25(8):611–18.
Rami de Cap M, et al. Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group . Leuk Lymphoma . 2023;64(5):972–80.
Shomali W, et al. Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group . Leukemia . 2023;37(5):981–87.
Small C, et al. Profiling endogenous, environmental, and infectious disease mutational signatures in blastic plasmacytoid dendritic cell neoplasms . Int J Lab Hematol . 2023;10.1111/ijlh.14108.
Tomlinson B, et al. Transplantation referral patterns for patients with newly diagnosed higher-risk myelodysplastic syndromes and acute myeloid leukemia at academic and community sites in the Connect Myeloid Disease Registry: Potential barriers to care . Transplant Cell Ther . 2023;29(7):460.e1–e9.
Valent P, et al. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes . Allergy . 2023;78(1):47–59.
Bou Zerdan M, et al. Recent advances in the treatment and supportive care of POEMS syndrome . J Clin Med . 2022;11(23):7011.
Carter-Febres M, et al. Hemophagocytic lymphohistiocytosis associated with T cell acute lymphoblastic leukemia . Int J Lab Hematol . 2022;44(1):15–16.
Genzen JR, et al. Integrity of SARS-CoV-2 laboratory-developed tests . JAMA . 2022;328(5):478.
Gerds AT, et al. Myeloproliferative neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology . J Natl Compr Canc Netw . 2022;20(9):1033–62.
Gotlib J, et al. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Disease (ECNM-AIM) response criteria in advanced systemic mastocytosis . J Allergy Clin Immunol Pract . 2022;10(8):2025–e1.
Hoermann G, et al. Standards of genetic testing in the diagnosis and prognostication of systemic mastocytosis in 2022: Recommendations of the EU-US Cooperative Group . J Allergy Clin Immunol Pract. 2022;10(8):1953–63.
Kanagal-Shamanna R, et al. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group . Mod Pathol . 2022;35(4):470–79.
Pyatilova P, et al. Refined treatment response criteria for indolent systemic mastocytosis proposed by the ECNM-AIM consortium . J Allergy Clin Immunol Pract . 2022;10(8):2015–24.
Simpson SJ, et al. 36-year-old male with X-linked congenital sideroblastic anemia presenting as chronic microcytic anemia with iron overload . Int J Lab Hematol 2022;44(1):69–71.
Sotlar K, et al. Standards of pathology in the diagnosis of systemic mastocytosis: recommendations of the EU-US Cooperative Group . J Allergy Clin Immunol Pract . 2022;10(8):1986–e2.
Valent P, et al. Global classification of mast cell activation disorders: An ICD-10-CM-adjusted proposal of the ECNM-AIM consortium . J Allergy Clin Immunol Pract . 2022;10(8):1941–50.
Valent P, et al. Personalized management strategies in mast cell disorders: ECNM-AIM user’s guide for daily clinical practice . J Allergy Clin Immunol Pract . 2022;10(8):1999–36.
DeAngelo DJ, et al. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial . Nat Med . 2021;27(12):2183–91.
Carter Febres M, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS)-associated hemophagocytic lymphohistiocytosis (HLH), an important and underrecognized HLH mimic: A case report. Pediatr Blood Cancer . 2021;68(2):e28657.
George TI, et al. Diagnosis of rare subtypes of acute myeloid leukaemia and related neoplasms . Pathology . 2021;53(3):312–27.
Gotlib J, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial . Nat Med . 2021;27(12):2192–99.
Gotlib J, et al. Proceedings from the inaugural American Initiative in Mast Cell Diesease (AIM) Investigator Conference . J Allergy Clin Immunol . 2021;147(6):2043–52.
Han SY, et al. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Adv. 2021;5(10):2481–89.
Kelemen K, et al. Eosinophilia/hypereosinophilia in the setting of reactive and idiopathic causes, well-defined myeloid or lymphoid leukemias, or germline disorders. Am J Clin Pathol . 2021;155(2):179–210.
King RL, et al. Reactive eosinophil proliferations in tissue and the lymphocytic variant of hypereosinophilic syndrome. Am J Clin Pathol . 2021;155(2):211–38.
Lozano-Chinga M, et al. Bone marrow necrosis in pediatric malignancies: 10-year retrospective review and review of literature . Pediatr Blood Cancer . 2021;68(3):e28806.
Ok CY, et al. Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/ MPL/ CALR) and SF3B1 . Mod Pathol . 2021;34(1):20–31.
Ozturk K, et al. Non-hematologic diagnosis of systemic mastocytosis: Collaboration of radiology and pathology . Blood Rev . 2021;45:100693.
Patel JL, et al. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes . Int J Lab Hematol . 2021;43(3):426–32.
Pozdnyakova O, et al. Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangements of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2. Am J Clin Pathol . 2021;155(2):160–78.
Rimsza L, et al. Addressing the challenges of eosinophilia and mastocytosis. Am J Clin Pathol . 2021;155(2):156–59.
Tzankov A, et al. Mastocytosis . Am J Clin Pathol . 2021;155(2):239–66.
Ustun C, et al. Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure . Int J Lab Hematol . 2021;43(1):e19–e25.
Weinberg OK, et al. Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group . Mod Pathol . 2021;34(7):1358–66.
Foucar K, et al. Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study . Int J Lab Hematol . 2020;42(4):418–22.
George TI. Evolution of the International Journal of Laboratory Hematology . Int J Lab Hematol . 2020;42(Suppl 1):6–7.
Gerds AT, et al. Myeloid/lymphoid neoplasms with eosinophilia and TK fusion genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology . J Natl Compr Canc Netw . 2020;18(9);1248–69.
Hartmann K, et al. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis . J Allergy Clin Immunol . 2020;146(2):356–66.e4.
Hayward CPM, et al. Patient advocacy and its importance to laboratory medicine practice. Int J Lab Hematol . 2020;42(Suppl 1):21–2.
Pollyea DA, et al. Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/ AML Disease Registry . EJHaem . 2020;1(1):58–68.
Reiter A, et al. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis . Blood . 2020;135(16):1365–76.
Utz JL, et al. "Soccer-ball" lymphocytosis . J Am Osteopath Assoc , 2020;120(4):286.
Valent P, et al. Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts . Theranostics . 2020;10(23):10743–68.
Bahr TM, et al. The Neonatal Acute Bilirubin Encephalopathy Registry (NABER): background, aims, and protocol . Neonatology . 2019;115(3):242–46.
Corean JL,et al. Bone marrow findings in metastatic melanoma, including role of BRAF immunohistochemistry . Int J Lab Hematol . 2019;41(4):550–60.
Gotlib J, et al. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis .Blood Adv . 2019;3(15):2264–71.
Hoffmann JC, et al. Rosai-Dorfman disease of the breast with variable IgG4+ plasma cells: a diagnostic mimicker of other malignant and reactive entities . Am J Surg Pathol . 2019;43(12), 1653–60.
Karner K,et al. Current aspects of clonal hematopoiesis: implications for clinical diagnosis . Ann Lab Med . 2019;39(6):509–14.
Li P, et al. Revisiting diagnostic criteria for myelodysplatic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: borderline cases without anemia exist . Int J Lab Hematol . 2019;41(3):345–52.
Bruegel M, et al. Multicenter evaluation of the cobas m 511 integrated hematology analyzer . Int J Lab Hematol. 2018;40(6):672–82.
Christensen RD, et al. Acute neonatal bilirubin encephalopathy in the state of Utah 2009-2018 . Blood Cells Mol Dis . 2018;72:10–13.
DeAngelo DJ, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial . Leukemia . 2018;32(2):470–78.
Goyal T, et al. T-cell large granular lymphocytic leukemia and coexisting B-cell lymphomas: a study from the bone marrow pathology group . Am J Clin Pathol . 2018;149(2):164–71.
Hatch EW, et al. Variability of PD-L1 expression in mastocytosis . Blood Adv . 2018;2(3):189–99.
Jennings SV, et al. Patient perceptions in mast cell disorders . Immunol Allergy Clin North Am . 2018;38(3):505–25.
Margolskee E, et al. A reevaluation of erythroid predominance in acute myeloid leukemia using the updated WHO 2016 criteria . Mod Pathol . 2018;31(6):873–80.
Sumarriva Lezama L, et al. An analysis of blastic plasmacytoid dendritic cell neoplasm with translocations involving the MYC locus identifies t(6;8)(p21;q24) as a recurrent cytogenetic abnormality . Histopathology . 2018;73(5):767–76.
Ustun C, et al. Core-binding factor acute myeloid leukemia with t(8; 21): risk factors and a novel scoring system (I-CBFit). Cancer Med. 2018;7(9):4447–55.
Gars E, et al. A replicable CD271+ mesenchymal stromal cell density score: bringing the dysfunctional myelodysplastic syndrome niche to the diagnostic laboratory . Leuk Lymphoma . 2017;58(7):1730–32.
George TI, et al. Evaluation of testing of acute leukemia samples: survey result from the College of American Pathologists . Arch Pathol Lab Med. 2017;141(8):1101–06.
Rogers HJ, et al. Most myeloid neoplasms with deletion of chromosome 16q are distinct from acute myeloid leukemia with inv(16)(p13.1q22): A Bone Marrow Pathology Group multicenter study . Am J Clin Pathol . 2017;147(4):411–19.
Valent P, et al. Midostaurin: a magic bullet that blocks mast cell expansion and activation . Ann Oncol . 2017;28(10):2367–76.
Wang SA, et al. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome . Haematologica . 2017;102(8):1352–60.
Connect Sign In
